blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News flashes

New version of the European Patent Register - SPC information for Unitary Patents.

2024-03-06

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3631445

EP3631445 - METHODS OF DETERMINING THERAPIES BASED ON SINGLE CELL CHARACTERIZATION OF CIRCULATING TUMOR CELLS (CTCS) IN METASTATIC DISEASE [Right-click to bookmark this link]
StatusGrant of patent is intended
Status updated on  23.01.2024
Database last updated on 07.06.2024
FormerExamination is in progress
Status updated on  20.12.2023
FormerGrant of patent is intended
Status updated on  31.08.2023
FormerExamination is in progress
Status updated on  21.07.2023
FormerGrant of patent is intended
Status updated on  23.03.2023
FormerExamination is in progress
Status updated on  03.12.2021
FormerRequest for examination was made
Status updated on  06.03.2020
FormerThe international publication has been made
Status updated on  08.12.2018
Most recent event   Tooltip24.05.2024New entry: Payment of fee for grant 
24.05.2024New entry: Payment of fee for publishing/printing 
Applicant(s)For all designated states
Epic Sciences, Inc.
9381 Judicial Drive, Suite 200
San Diego, CA 92121 / US
[2020/15]
Inventor(s)01 / DITTAMORE, Ryan
9381 Judicial Drive
Suite 200
San Diego, CA 92121 / US
 [2023/39]
Former [2020/15]01 / DITTAMORE, Ryan
9381 Judicial Drive
Suite 200
San Diego, CA 92121 / US
Representative(s)Jones Day
Rechtsanwälte, Attorneys-at-Law, Patentanwälte
Prinzregentenstrasse 11
80538 München / DE
[2020/15]
Application number, filing date18810303.001.06.2018
[2020/15]
WO2018US35581
Priority number, dateUS201762514642P02.06.2017         Original published format: US 201762514642 P
US201762531725P12.07.2017         Original published format: US 201762531725 P
[2020/15]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2018222979
Date:06.12.2018
Language:EN
[2018/49]
Type: A1 Application with search report 
No.:EP3631445
Date:08.04.2020
Language:EN
The application published by WIPO in one of the EPO official languages on 06.12.2018 takes the place of the publication of the European patent application.
[2020/15]
Search report(s)International search report - published on:US06.12.2018
(Supplementary) European search report - dispatched on:EP29.04.2021
ClassificationIPC:G01N33/50, G01N33/574, G01N33/52, C12N5/09, C12N5/095, C12N5/22
[2020/15]
CPC:
G01N33/57434 (EP,US); G01N1/30 (US); G01N33/5011 (US);
G01N33/533 (US); G01N33/57484 (US); G01N2500/10 (US);
G01N2800/52 (EP) (-)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2020/15]
TitleGerman:VERFAHREN ZUR BESTIMMUNG VON THERAPIEN AUF DER BASIS VON EINZELZELLCHARAKTERISIERUNG VON ZIRKULIERENDEN TUMORZELLEN (CTCS) BEI METASTASIERENDEN ERKRANKUNGEN[2020/15]
English:METHODS OF DETERMINING THERAPIES BASED ON SINGLE CELL CHARACTERIZATION OF CIRCULATING TUMOR CELLS (CTCS) IN METASTATIC DISEASE[2020/15]
French:MÉTHODES DE DÉTERMINATION DE THÉRAPIES SUR LA BASE D'UNE CARACTÉRISATION CELLULAIRE UNIQUE DE CELLULES TUMORALES CIRCULANTES (CTC) DANS UNE MALADIE MÉTASTATIQUE[2020/15]
Entry into regional phase27.12.2019National basic fee paid 
27.12.2019Search fee paid 
27.12.2019Designation fee(s) paid 
27.12.2019Examination fee paid 
Examination procedure27.12.2019Examination requested  [2020/15]
25.11.2021Amendment by applicant (claims and/or description)
03.12.2021Despatch of a communication from the examining division (Time limit: M06)
30.05.2022Reply to a communication from the examining division
24.03.2023Communication of intention to grant the patent
21.07.2023Disapproval of the communication of intention to grant the patent by the applicant or resumption of examination proceedings by the EPO
01.09.2023Communication of intention to grant the patent
20.12.2023Disapproval of the communication of intention to grant the patent by the applicant or resumption of examination proceedings by the EPO
24.01.2024Communication of intention to grant the patent
23.05.2024Fee for grant paid
23.05.2024Fee for publishing/printing paid
Fees paidRenewal fee
15.06.2020Renewal fee patent year 03
14.06.2021Renewal fee patent year 04
31.03.2022Renewal fee patent year 05
31.03.2023Renewal fee patent year 06
12.04.2024Renewal fee patent year 07
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Documents cited:Search[I]US2015212089  (DITTAMORE RYAN [US]) [I] 1,2,5,6,8-12 * the whole document * * abstract * * claims 1, 3, 21 * * paragraph [0040] - paragraph [0041] * * paragraph [0050] *;
 [I]WO2015112955  (EPIC SCIENCES INC [US]) [I] 1,2,5,6,8-12 * the whole document * * claims 1,7 * * paragraphs [0027] , [0 53] , [0 57] *;
 [I]WO2016196284  (EPIC SCIENCES INC [US]) [I] 1,2,5,6,8-12 * the whole document * * claims 1, 2, 9, 12 *;
 [I]  - H. BELTRAN ET AL, "The Initial Detection and Partial Characterization of Circulating Tumor Cells in Neuroendocrine Prostate Cancer", CLINICAL CANCER RESEARCH, US, (20160315), vol. 22, no. 6, doi:10.1158/1078-0432.CCR-15-0137, ISSN 1078-0432, pages 1510 - 1519, XP055382275 [I] 1,2,5,6,8-12 * the whole document * * figure 3 *

DOI:   http://dx.doi.org/10.1158/1078-0432.CCR-15-0137
International search[Y]US2016266127  (KUHN PETER [US], et al) [Y] 1-3, 13-15, 21-23, 33-35, 45-47, 53-55 * . Especially para [0006], [0010]. *;
 [Y]  - SCHER et al., "Baseline CTC subtype to predict outcomes on mCRPC patients (pts) receiving enzalutamide (E) compared to abiraterone (A", J Clin Oncol, vol. 35, no. 15, doi:10.1200/JCO.2017.35.15_suppl.5070, (20170520), page 5070, URL: http://ascopubs.org/doi/abs/10.1200/JCO.2017.35.15_suppl.5070, XP009517907 [Y] 1-3, 13-15, 21-23, 33-35, 45-47, 53-55 * . Especially abstract. *

DOI:   http://dx.doi.org/10.1200/JCO.2017.35.15_suppl.5070
by applicantUS2016266127
    - MOHLER et al., J Natl Compr Canc Netw. 2013, (20140000), vol. 11, no. 12, pages 1471 - 1479
    - COOKSON et al., J Urol. 2013, (20130000), vol. 190, no. 2, pages 429 - 438
    - MEZYNSKI et al., Ann Oncol., (20120000), vol. 23, no. 11, pages 2943 - 2947
    - NOONAN et al., Ann Oncol., (20130000), vol. 24, no. 7, pages 1802 - 1807
    - PEZARO et al., Eur Urol, (20140000), vol. 66, no. 3, pages 459 - 465
    - MATEO et al., NEJM, (20150000), vol. 373, no. 18, pages 1697 - 708
    - ROBINSON et al., Cell, (20150000), vol. 161, no. 5, pages 1215 - 28
    - BALMANA et al., Ann Oncol., (20140000), vol. 25, pages 1656 - 63
    - DEL CONTE et al., Br J Cancer, (20140000), vol. 111, pages 651 - 9
    - ABKEVICH et al., Br J Cancer, (20121106), vol. 107, no. 10, pages 1776 - 82
    - MARQUARD et al., Biomark Res., (20150501), vol. 3, page 9
    - VOLLEBERGH et al., Breast Cancer Res., (20140000), vol. 16, no. 3, page 47
    - ISAKOFF et al., J. Clinical Oncol., (20150000), vol. 33, no. 17, pages 1902 - 9
    - PUNNOOSE et al., Br J Cancer, (20151020), vol. 113, no. 8, pages 1225 - 33
    - CRISTOFANILLI et al., N Engl J Med, (20040000), vol. 351, pages 781 - 91
    - KRZYWINSKI, M et al., "Circos: an Information Aesthetic for Comparative Genomics", Genome Res, (20090000), vol. 19, doi:10.1101/gr.092759.109, pages 1639 - 1645, XP055244408

DOI:   http://dx.doi.org/10.1101/gr.092759.109
    - POPOVA et al., Cancer Res., (20120000), vol. 72, no. 21, pages 5454 - 62
    - ZAFARANA, Cancer, (20120800), vol. 118, no. 16, page 4053
    - MARRINUCCI D. et al., Phys. Biol., (20120000), vol. 9
    - S. BRENNER et al., Nature Biotechnology, (20000000), vol. 18, no. 6, pages 630 - 634
    - SELF et al., Curr. Opin. Biotechnol., (19960000), vol. 7, pages 60 - 65
    - WATSON et al., Recombinant DNA, Scientific American Books
    - Genome Analysis: A Laboratory Manual Series, Cold Spring Harbor Laboratory Press, (19980000), vol. 1-4
    - "Polymerase chain reaction (PCR) can be carried out generally as in PCR Protocols", A Guide to Methods and Applications, Academic Press
    - ANGERER et al., Methods Enzymol., (19870000), vol. 152, pages 649 - 660
    - J. MARIONI, Genome Research, (20080000), vol. 18, no. 4, pages 1509 - 1517
    - A. MORTAZAVI, Nature Methods, (20080000), vol. 5, no. 7, pages 613 - 619
    - L. MORRISON et al., Labeling Fluorescence In Situ Hybridization Probes for Genomic Targets, Humana Press, (20020000), pages 21 - 40
    - BOXCOX, Royal Stat. Soc., (19640000), vol. 26, pages 211 - 246
    - MARRINUCCI et al., Phys Biol, (20120000), vol. 9, no. 1, page 016003
    - MARRINUCCI et al., Hum Pathol, (20070000), vol. 38, no. 3, pages 514 - 519
    - MARRINUCCI et al., Arch Pathol Lab Med, (20090000), vol. 133, no. 9, pages 1468 - 1471
    - MIKOLAJCZYK et al., J Oncol, (20110000), vol. 2011, page 252361
    - WERNER et al., J Circ Biomark, (20150000), vol. 4, page 3
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.